Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC
Дата публикации: 30-06-2026 07:06:00

Findings from the HARMONi-6 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
2Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma5730-06-2026
3Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026
4New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
5Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma0502-07-2026
6EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
7Precision therapy for metastatic prostate cancer improves survival2720-08-2024
8Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer0725-06-2026
9حقنة جديدة تبعث الأمل.. علاج واعد يقضي على أورام السرطان7801-06-2026
10Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors0725-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.